BioMarin Pharmaceutical Inc. (BMRN) Reports Q1 Loss of $0.04
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Join SI Premium – FREE
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported Q1 EPS of ($0.04), $0.06 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $109.46 million versus the consensus estimate of $103.8 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
